Business Wire (May 9, 2013)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,011 people get BCRX articles and Market Currents by email alert.
Get email alerts on BCRX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (May 7, 2013)
-
-
-
Business Wire (Apr 23, 2013)
-
-
Business Wire (Apr 16, 2013)
-
-
-
-
-
Business Wire (Apr 1, 2013)
-
Business Wire (Mar 25, 2013)
-
-
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 5, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
BioCryst Drug Receives Recommendation for Pediatric Approval in JapanMichael Murphy • Mon, Sep 27, 2010 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
The Best And Worst Of Earnings SeasonBespoke Investment Group • Fri, Nov 16, 2012 -
Today's Market News To Trade On: 5 Stocks Moving On NewsMatthew Smith • Fri, Nov 9, 2012
-
-
-
-
What Moves Biotech Stocks? Ed Arce Has AnswersLife Sciences Report • Thu, Oct 18, 2012 -
-
-
-
-
BioCryst Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptWed, Apr 28, 2010
-
BioCryst Pharmaceuticals, Inc. Q4 2009 Earnings Call TranscriptThu, Feb 4, 2010
-
BioCryst Pharmaceuticals, Inc. Q4 2007 Earnings Call TranscriptMon, Mar 24, 2008
-
Business Wire (May 9, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 23, 2013)
-
Business Wire (Apr 16, 2013)
-
at MarketWatch.com (Apr 8, 2013)
-
at MarketWatch.com (Apr 8, 2013)
-
Business Wire (Apr 1, 2013)
-
Business Wire (Mar 25, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 5, 2013)
-
Business Wire (Jan 2, 2013)
-
Business Wire (Dec 7, 2012)
-
Business Wire (Nov 30, 2012)
-
Business Wire (Nov 12, 2012)
-
at MarketWatch.com (Nov 8, 2012)
-
Business Wire (Nov 8, 2012)
-
Business Wire (Nov 7, 2012)
-
Business Wire (Nov 1, 2012)
-
Business Wire (Oct 30, 2012)
-
Business Wire (Oct 18, 2012)
BCRX vs. ETF Alternatives
Company Description
BioCryst Pharmaceuticals, Inc. is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. BioCryst integrates the disciplines of biology, crystallography, medicinal chemistry and computer... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 7, 6:08 AM BioCryst Pharm (BCRX): Q1 EPS of -$0.09 beats by $0.03. Revenue of $3.6M beats by $2.29M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, May 7, 12:05 AM Notable earnings before Tuesday’s open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC 2 Comments [Earnings]
- Monday, May 6, 5:30 PM Notable earnings before Tuesday's open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC Comment! [Earnings]
- Wednesday, April 24, 11:37 AM BioCryst Pharmaceuticals (BCRX +8.3%) pops again today on bird flu concerns out of China, this time that catalyst comes from comments made out of the World Health Organization today, saying that the H7N9 is "one of the most lethal" strains of the bird flu virus compared to one that has killed about 371 since 2003. Since being discovered in March, the H7N9 has killed 22 and inflected just over 100 people. Comment! [Healthcare, Global & FX, On the Move]
- Tuesday, April 16, 10:44 AM Shares in BioCryst Pharmaceuticals (BCRX +3.8%) are higher today after the company announces it's completed its Type C meeting on peramivir with the FDA and confirmed that its proposed New Drug Application content supports a reviewable submission for the indication of acute uncomplicated influenza. The company says it's now in the process of requesting a pre-NDA meeting to reach agreement on a complete NDA submission and to address review issues identified in the minutes. Comment! [Healthcare, On the Move]
-
Tuesday, April 16, 9:10 AM
Premarket gainers: NWBO +9%. GFI +7%. BCRX +7%. HK +7%. AU +7%. NG +6%. AUQ +6%. SAND +6%. GOLD +5%. KGC +5%.
Losers: LDK -16%. SRPT -11%. 1 Comment [On the Move] - Monday, April 15, 10:28 AM BioCryst (BCRX +5%) moves up again today, adding to last week's gains as the number of bird flu cases in China continues to increase. Recent reports now have the death toll at 14, with 61 confirmed cases. The stock has climbed nearly 21% in the past week, after China moved to expedite approval of it's anti-flu drug, Permavir, after six new cases of the H7N9 virus were diagnosed. Comment! [Healthcare, Global & FX, On the Move]
-
Monday, April 15, 9:15 AM
Premarket gainers: S +16%. SVA +13%. BCRX +10%. LIFE +8%. NFP +7%. MGT +7%. TMO +6%. THRX +5%. NVAX +5%.
Losers: AAU -15%. MTL -10%. AUQ -11%. HMY -9%. NGD -8%. CEF -8%. SLW -8%. SAND -9%. KGC -7%. AUY -7%. GOLD -7%. MUX -7%. DSCO -7%. IAG -6%. SVM -6%. GG -6%. PAAS -6%. EGO -6%. AU -5%. CDE -5%. Comment! [On the Move] - Monday, April 15, 8:39 AM Biotechs rise in early trading as the death toll from the new avian flu strain jumps to 13. Sinovac (SVA) is preparing immunizations and can manufacture 30-40M doses annually, according to Bloomberg. Meanwhile, investors continue to bet BioCryst's (BCRX) peramavir could have a role to play. Premarket moves: SVA +9.6%, BCRX +7.4%, NVAX +5%. Comment! [On the Move, Healthcare]
- Tuesday, April 9, 8:03 AM BioCryst Pharma (BCRX) gets an upgrade to Buy from Hold at MLV whose analyst Ed Arce called the stock "a complete turnaround story" yesterday. The stock has rallied hard on speculation the company's drug peramavir may play a role in helping China combat a new strain of avian flu. Some however, believe the hype is overdone. Shares +4.7% premarket. Comment!
- Monday, April 8, 3:30 PM JMP Securities analyst Lisa Bayko says the rally in BioCryst Pharma (BCRX +10%) on the China/Permivir news is overdone. She points out that BCRX has no patent in China for Peramivir, hasn't been involved in any drug approval, and "won't receive economics from use there." BCRX appears to agree. saying it doesn't even have a partner or any in-country operations in the region. TheStreet.com's Adam Fuerstein quips that the drug developer "isn't likely to see a dime" from drug sales there. Comment! [Healthcare, On the Move]
-
Monday, April 8, 9:10 AM
Premarket gainers: LUFK +38%. BSDM +34%. BCRX +18%. UNXL +15%. GOL +10%. TSL +7%.
Losers: OMPI -6%. DCTH -5%. Comment! [On the Move] - Monday, April 8, 8:28 AM BioCryst Pharmaceuticals (BCRX) looks to post outsized gains for the second straight session as China expedites approval for its Peramivir drug amid worries about a new strain of avian flu. The shares rose sharply on Friday as the death toll from the new virus rose to six. Shares +21% premarket. Comment! [Healthcare, On the Move]
- Friday, April 5, 11:09 AM BioCryst Pharmaceuticals (BCRX +17.4%) pops on news that six deaths in China have been linked to a new strain of avian flu. BCRX is developing peramivir, which has been shown in preclinical studies to help treat highly virulent strains of influenza - including the bird flu strain known as the H5N1 virus. Other drug stocks moving higher on the news: Pure Bioscience (PURE +15.6%), Hemispherx BioPharma (HEB +13.3%), Sinovac Biotech (SVA +7.8%), and Novavax (NVAX +1.1%). Comment! [Healthcare, On the Move]
- Monday, April 1, 9:11 AM Premarket gainers: KWK +33%. BCRX +30%. SNFCA +23%. TSLA +16%. AM +12%. VRNG +10%. PAL +6%. Comment! [On the Move]
- Monday, April 1, 8:29 AM BioCryst Pharmaceuticals (BCRX) receives a letter from FDA which it says "outlines a pathway by which an NDA [could be filed] seeking regulatory approval of intravenous permavir." Last November, shares were nearly cut in half after permavir disappointed in clinical trials. Shares +15% premarket. Comment! [Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
freefdawatchlist
http://stks.co/jE5o Stocks for Nov 1st: $CRUS, $ZUMZ, $ELLI, $BCRX, $OTEX http://stks.co/fEE2 - View all 0 replies
-
Michael Clark
BUY: PCLN, TXT, BCRX, JDSU. VIX. SHORT: SCHN, XOMA, CORT, AOBI. Momentum still down in markets. http://seekingalpha.com/p/j7sh - View all 5 replies
-
Michael Clark: He's a clown. Actually the markets move up and down like a breathing process. The talking head say this caused that and that caused this.
-
Michael Clark: In truth, the market breathed out; and will soon again breathe in. European system isn't fixed. They've said their in charge before.
-
Roy Manning III
BCRX has sold off alot. I would consider it a buy now. News on a Gout drug partner or their Hep C. patent could push the stock higher. - View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
LATEST REPLIES
-
Michael Clark
BUY: PCLN, TXT, BCRX, JDSU. VIX. SHORT: SCHN, XOMA, CORT, AOBI. Momentum still down in markets. http://seekingalpha.com/p/j7sh - View all 5 replies
-
Michael Clark: He's a clown. Actually the markets move up and down like a breathing process. The talking head say this caused that and that caused this.
-
Michael Clark: In truth, the market breathed out; and will soon again breathe in. European system isn't fixed. They've said their in charge before.
-
- View all 1 replies
-
-
- View all 1 replies
-